- EN
- ES
An official website of the Biotechnology Innovation Organization
BIO Clinical Trial Diversity Summit
BIO hosted its first-ever Summit on Increasing Diversity in Clinical Trials from June 24th – June 25th, 2021!
The two-day summit gathered thought leaders from community, patient, clinical research, policy and medical research organizations together with biopharmaceutical companies to design a comprehensive strategy to advance health equity in clinical trials with a focus on incorporating actionable solutions to execute real change. The program featured experts working on innovative solutions to create equitable research and promoted the sharing of best practices among panelists and attendees. Each day wrapped up with a networking session, designed to provide participants with an opportunity to create valuable, new connections while fostering existing relationships.
Learn more about the inspiring leaders (from patient organizations, government, biopharmaceutical companies, academia, tech startups, and more!) who spoke at BIO's June 2021 Summit.
BIO convened stakeholders from across the clinical development spectrum to engage in meaningful discussion on advancing health equity in clinical trials. Because ensuring clinical trial diversity is not just at the heart of BIO’s Equality Agenda— it’s driving the future development and availability of innovative medical products.
JUNE 24TH | 12:00 PM - 12:30 PM EST
- Dr. Cartier Esham, PhD, Chief Scientific Officer, Biotechnology Innovation Organization
- Dr. Michelle McMurry-Heath, MD, PhD CEO, Biotechnology Innovation Organization
- Dr. Loretta Christensen, MD, MBA, MSJ, FACS, Chief Medical Officer, Navajo Area Indian Health Service
JUNE 24TH | 12:30 PM - 1:50 PM EST
Community leaders and medical professionals that represent and understand underserved communities will discuss lessons learned from past mistakes in clinical research and the path forward for creating a more equitable clinical development process.
Moderator: Dr. Michelle McMurry-Heath, MD, PhD CEO, Biotechnology Innovation Organization
- Dr. Elena V. Rios, MD, MSPH, FACP, President & CEO, National Hispanic Medical Association, & President, National Hispanic Health Foundation
- Dr. Randall C. Morgan, Jr., MD, MBA, President & CEO, W. Montague Cobb/NMA Health Institute
- Silas Buchanan, CEO, Institute for eHealth Equity
- Tom Anderson, MPH, Executive Director, Association of American Indian Physicians (AAIP)
JUNE 24TH | 2:00 PM - 3:20 PM EST
Biopharmaceutical CEOs and industry leaders will discuss the social and business imperative of diverse participation in clinical trials and the best way to achieve it by sharing insights from the pandemic.
Moderator: Dr. Cartier Esham, PhD, Chief Scientific Officer, BIO
- Dr. Julie Gerberding, MD, MPH, Chief Patient Officer, Executive VP of Population Health, Global Policy, and Strategic Communications, Merck
- Staci Hargraves, VP, Portfolio Management, Janssen (Johnson & Johnson)
- Dr. Ted W. Love, MD, CEO, Global Blood Therapeutics
JUNE 24TH | 3:30 PM – 4:50 PM EST
Hear from executives and clinical development leaders that have set targets and enacted internal changes to increase clinical trial diversity.
Moderator: Dr. Barbara Bierer, MD, Director, Multi-Regional Clinical Trials Center
- Dr. Asha S. Collins, PhD, US Clinical Operations Head, Genentech
- Dr. Darryl Sleep, MD (MBBCh, FCS(SA)), Chief Medical Officer, Amgen
- Dr. Lisa Dunkle, MD, VP of Clinical Development, Global Medical Lead for COVID-19 Vaccine, Novavax
- Dr. Melanie Ivarsson, PhD, MBA, Chief Development Officer, Moderna
- Tamar Thompson, MPH, VP, US Government Affairs & Policy, Alexion Pharmaceuticals
JUNE 25TH | 12:00 PM – 12:30 PM EST
- Dr. Cartier Esham, PhD, Chief Scientific Officer, Biotechnology Innovation Organization
- Dr. Reed V. Tuckson, MD, FACP, Managing Director, Tuckson Health Connections LLC
JUNE 25TH | 12:30 PM – 1:50 PM EST
Industry leaders and researchers will discuss real world examples of trial design tools that enabled more inclusivity in trials during the pandemic and the implications for their continued use.
Moderator: Esther Krofah, MPP, Executive Director, Faster Cures, a Center of the Milken Institute
- Dr. Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead
- Dr. Janelle Sabo, PharmD, VP of Clinical Capabilities: Clinical Design, Delivery & Analytics (CDDA), Eli Lilly
- John L. Newby II, JD, CEO, Virginia Biotechnology Association
- Dr. Stacey J. Adam, PhD, Associate VP of Research Partnerships, Foundation for the National Institutes of Health (FNIH)
JUNE 25TH | 2:00 PM – 3:20 PM EST
Accessible technologies are critical to creating an inclusive clinical trial network. Experts will provide an overview of what trial designs, data and tools can enable diverse patient participation.
Moderator: Dr. Cartier Esham, PhD, Chief Scientific Officer, BIO
- Carolyn Magill, MBA, CEO & Board Director, Aetion
- Dr. Cynthia Verst, PhD, President, R&DS Design & Delivery Innovation, IQVIA
- David Coman, MBA, CEO, Science 37
- Matt Walz, MBA, CEO, Trialbee
- Maulik Mehta, MBA, Chief Business Officer, TriNetX
The Imperative of Community & Patient Engagement: Building Trust in and Awareness of Opportunities…
JUNE 25TH | 3:30 PM – 4:50 PM EST
Engaging with patients and community advocates is critical to advancing education about and awareness of opportunities to participate in clinical trials. Hear from leading advocates and thought leaders about how build, support and engage community engagement networks.
Moderator: Donna R. Cryer, JD, President & CEO of the Global Liver Institute
- Debra Fraser-Howze, Principle, D. Fraser Associates, Founder, Choose Healthy Life
- Dr. James Powell, MD, Principal Investigator, National Medical Association, Project IMPACT
- Kim Cantor, MPA, Senior Director, Pyxis Partners, NIH All of Us Community and Provider Partner Network
- Maya Bermingham, JD, Senior VP, Public Policy and Government Affairs, Regeneron
- Dr. Stephaun Wallace, PhD, Director of External Relations, HIV Vaccine Trials Network
BIO Clinical Trial: The Power of Participation does not provide medical advice, diagnosis or treatment.